Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

RNhale

Financiado

Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage...

Dry Powder Formulation of RNA Nanoparticles for Inhalation and Improved Storage and Transport Conditions RNhale aims to establish technical and commercial proof-of-concept for our existing and protected protocols to be transformed into a platform technology with the long-term goal of licensing agreements with large pharmaceutical com... ver más

31/12/2023

LMU MUENCHEN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

LMU MUENCHEN

150.00K€ | Lider

Proyectos interesantes

CodeSphere CodeSphere Discovering Therapeutic Nanoparticles by Molecu... 150K€ Cerrado

DNANOMETAL Design of metal-stabilized DNA and RNA nanoconstructs potent... 215K€ Cerrado

COMPACT Collaboration on the Optimisation of Macromolecular Pharmac... 30M€ Cerrado

PID2019-107500RB-I00 BIOMORPHIC PLATFORMS FOR THE PULMONARY DELIVERY OF NANOTHERA... 97K€ Cerrado

RTC-2016-5260-1 Ensayo fase I para determinar el perfil farmacocinético y la... 605K€ Cerrado

IJCI-2016-30558 Farmacocinética de nanopartículas 64K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-06-15
Fecha Fin: 2023-12-31

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto RNhale aims to establish technical and commercial proof-of-concept for our existing and protected protocols to be transformed into a platform technology with the long-term goal of licensing agreements with large pharmaceutical companies which are equipped for continuous manufacturing of large scales of dry powder RNA formulations. RNhale will assess the commercial positioning of a platform technology for spray-drying RNA nanoparticles (NPs). While RNA medicines have revolutionized how we can address a pandemic, RNA therapeutics have not yet broadly changed patient outcomes but are specifically used for very limited indications due to two main reasons: (i) the high immunogenicity and poor stability of RNA; and (ii) the accumulation of nano-encapsulated RNA in the liver and resulting poor targetability of other organs with RNA-loaded NPs. These shortcomings have been addressed in my current ERC project Novel Asthma Therapy by spray-drying polymer-based RNA NPs. RNhale will refine existing protocols for spray-drying RNA NPs made with diverse RNA NPs to overcome current challenges by: 1) improving storage and transport conditions of spray-dried RNA medicines in general; and 2) gaining access to delivery beyond the liver via inhalation delivery to the lung.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores